DK288686A - PHARMACEUTICAL PREPARATIONS - Google Patents

PHARMACEUTICAL PREPARATIONS Download PDF

Info

Publication number
DK288686A
DK288686A DK288686A DK288686A DK288686A DK 288686 A DK288686 A DK 288686A DK 288686 A DK288686 A DK 288686A DK 288686 A DK288686 A DK 288686A DK 288686 A DK288686 A DK 288686A
Authority
DK
Denmark
Prior art keywords
denotes
carbon atoms
hydrogen atom
pharmaceutical preparations
hydrocarbon radical
Prior art date
Application number
DK288686A
Other languages
Danish (da)
Other versions
DK167531B1 (en
DK288686D0 (en
Inventor
Walter Klose
Gerald Kirsch
Andreas Huth
Wolfgang Froehlich
Henry Laurent
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of DK288686A publication Critical patent/DK288686A/en
Publication of DK288686D0 publication Critical patent/DK288686D0/en
Application granted granted Critical
Publication of DK167531B1 publication Critical patent/DK167531B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B1/00—Engines characterised by fuel-air mixture compression
    • F02B1/02—Engines characterised by fuel-air mixture compression with positive ignition
    • F02B1/04—Engines characterised by fuel-air mixture compression with positive ignition with fuel-air mixture admission into cylinder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Pharmaceutical preparations for the local treatment of inflammations comprise, as active compound, one or two compounds of the general formula I <IMAGE> in which X denotes an oxygen atom or a methylene group, R1 and R2 denote a hydrogen atom or a hydrocarbon radical having at most eight carbon atoms which is optionally interrupted by an oxygen atom, R3 denotes a hydrogen atom or a hydrocarbon radical having a most eight carbon atoms which is optionally substituted by an oxo group, and R4 denotes a hydrogen atom or an alkyl group having at mot four carbon atoms.
DK288686A 1984-10-19 1986-06-19 Pyrrolidinone and oxazolidinone derivatives, and their use for producing pharmaceutical preparations DK167531B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3438839 1984-10-19
DE19843438839 DE3438839A1 (en) 1984-10-19 1984-10-19 PHARMACEUTICAL PREPARATIONS
PCT/DE1985/000472 WO1986002268A1 (en) 1984-10-19 1985-10-18 Pharmaceutical preparations
DE8500472 1985-10-18

Publications (3)

Publication Number Publication Date
DK288686A true DK288686A (en) 1986-06-19
DK288686D0 DK288686D0 (en) 1986-06-19
DK167531B1 DK167531B1 (en) 1993-11-15

Family

ID=6248597

Family Applications (1)

Application Number Title Priority Date Filing Date
DK288686A DK167531B1 (en) 1984-10-19 1986-06-19 Pyrrolidinone and oxazolidinone derivatives, and their use for producing pharmaceutical preparations

Country Status (8)

Country Link
EP (1) EP0198919B1 (en)
JP (2) JPH0742229B2 (en)
AU (2) AU5095885A (en)
DE (2) DE3438839A1 (en)
DK (1) DK167531B1 (en)
FI (1) FI862590A (en)
NO (1) NO164897C (en)
WO (1) WO1986002268A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783591A (en) * 1984-10-19 1998-07-21 Schering Aktiengesellschaft Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation
US4681940A (en) * 1985-11-19 1987-07-21 American Home Products Corporation 5-[3-[[2-quinolyl]methoxy]phenyl]-1,3-oxazoles
DE3639225A1 (en) * 1986-11-14 1988-05-19 Schering Ag USE OF 5- (SUBST. PHENYL) -OXAZOLIDINONE DERIATES AS PSYCHOPHARMAKA
WO1988009661A1 (en) * 1987-06-10 1988-12-15 Pfizer Inc. Oxazolidin-2-one derivatives as hypoglycemic agents
ATE106243T1 (en) * 1988-03-24 1994-06-15 Sankyo Co USE OF ISOXAZOLINONES AS CEREBRO-ACTIVE MEDICATIONS.
US5420154A (en) * 1990-08-03 1995-05-30 Smithkline Beecham Corp. TNF inhibitors
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
AU706159B2 (en) * 1995-02-10 1999-06-10 Schering Aktiengesellschaft Pharmaceutical preparations for TNF inhibition
DE19540475A1 (en) * 1995-10-20 1997-04-24 Schering Ag Chiral methylphenyloxazolidinones
US6770658B2 (en) * 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
IL161317A0 (en) * 2001-10-16 2004-09-27 Memory Pharm Corp 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
WO2004098592A1 (en) * 2003-05-06 2004-11-18 Senju Pharmaceutical Co. Ltd. Composition containing oxazolidinone derivative
TW200732313A (en) 2005-12-15 2007-09-01 Astrazeneca Ab Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2413935A1 (en) * 1974-03-20 1975-10-16 Schering Ag 4- (POLYALCOXY-PHENYL) -2-PYRROLIDONE
SU888821A3 (en) * 1976-12-03 1981-12-07 Шеринг Аг (Инофирма) Method of preparing 5-(substituted phehyl)-oxazolidinones or their sulphur-containing analogs
DE2655369A1 (en) * 1976-12-03 1978-06-08 Schering Ag 5- (SUBST. PHENYL) -OXAZOLIDINONE AND THEIR SULFUR ANALOGS AND PROCESS FOR THEIR PRODUCTION

Also Published As

Publication number Publication date
DK167531B1 (en) 1993-11-15
JPH0761978A (en) 1995-03-07
EP0198919A1 (en) 1986-10-29
AU4765390A (en) 1990-05-03
NO164897B (en) 1990-08-20
NO862439D0 (en) 1986-06-18
AU5095885A (en) 1986-05-02
DE3438839A1 (en) 1986-04-24
FI862590A0 (en) 1986-06-17
NO862439L (en) 1986-06-18
DK288686D0 (en) 1986-06-19
JPH0742229B2 (en) 1995-05-10
FI862590A (en) 1986-06-17
JP2669494B2 (en) 1997-10-27
NO164897C (en) 1990-11-28
JPS62501289A (en) 1987-05-21
DE3576118D1 (en) 1990-04-05
WO1986002268A1 (en) 1986-04-24
EP0198919B1 (en) 1990-02-28

Similar Documents

Publication Publication Date Title
FI93351C (en) A process for the preparation of therapeutically useful polyethylene glycol carbamates
DK288686A (en) PHARMACEUTICAL PREPARATIONS
AU7554987A (en) Solutions of oxazaphosphorins having improved stability and process for the preparation thereof
SE8604950D0 (en) DEMENTIA IMPROVING AND THERAPEUTIC AGENTS
AU541413B2 (en) 2-(1,4-benzodioxan-2-ylalicyl)imidazoles
DE3477488D1 (en) Polymethoxybenzyl piperazine derivatives, processes for their preparation and pharmaceutical compositions containing said derivatives
NO164351C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 5-ALKYL-L-PHENYL-2-PIPERAZINOALKYLPYRAZOLINE-3-ON COMPOUNDS.
FI870090A (en) LAONGKEDJADE ALKYLRESORCINOLPHOSFITER.
ATE188217T1 (en) 1,2,3,4,10,14B-HEXAHYDRODIBENZO-C,F)PYRAZINO-1, - A)AZEPINO DERIVATIVES
MX170732B (en) COMPOSITION OF SUCCINIMIDE DERIVATIVES AND THEIR USE
NO871575L (en) PROCEDURE FOR THE PREPARATION OF 1,5-BENZTIAZEPINE DERIVATIVES.
ES8702379A1 (en) Tetrazolcarboxanilid derivatives.
AR247737A1 (en) Cycloalkylthiazole derivatives
GR3019921T3 (en) Alkylaminoalkylamino and -ether compounds as well as processes and intermediates for their preparation, and medicaments containing these compounds
SE7902867L (en) ANTI-COMPLEMENTARY MEANS
ES8702392A1 (en) Thiadiazinone compounds, process for their preparation, and pharmaceutical compositions containing them.
SE8303719D0 (en) NOVEL EBURNANE OXIME DERIVATIVES AND PROCESS FOR PREPARING SAME
ATE15898T1 (en) NEW N-SUBSTITUTED POLYGLYCIDYLURAZOLE COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS.
ATE40677T1 (en) DIAMINDERIVES.
ATE26575T1 (en) SUBSTITUTED 9H-8-OXO-PYRIMIDO(2,1-F)PURIN-2,4-DIONES, PROCESSES FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
ATE61352T1 (en) 4-HYDROXY-4-(SUBSTITUTED ALKENYL)CYCLOHEXANECARBONS|URE.
FI943596A (en) A process for the preparation of therapeutically useful macrolide compounds
CH610887A5 (en) Process for the preparation of new 7-benzoyl-2-indolinones
AU8292787A (en) Fluorine-containing macrolide compounds and their use
SE8303718L (en) E-HOMO ENURNAND DERIVATIVES, PROCEDURE FOR PREPARING THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE ASSOCIATIONS

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired